NDC product
NovoLog Mix 70/30
NDC 0169-2201 · Novo Nordisk Pharmaceutical Industries, LP
Key facts
| Product NDC | 0169-2201 |
|---|---|
| Proprietary name | NovoLog Mix 70/30 |
| Nonproprietary name | insulin aspart |
| Substances | INSULIN ASPART |
| Dosage form | INJECTION, SUSPENSION |
| Route | SUBCUTANEOUS |
| Labeler | Novo Nordisk Pharmaceutical Industries, LP |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | BLA |
| Application number | BLA021172 |
| Pharmacologic classes | Insulin Analog [EPC], Insulin [CS] |
| Marketing start | Sep 11, 2002 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: